The use of psilocybin (magic mushrooms) for therapeutic purposes gains traction Last month, the NBA and its players association reached a tentative deal that the league would no longer test players for marijuana. Indeed, the NBA is lifting its ban on marijuana in the new collective bargaining agreement. Meanwhile, the NFL and its players agreed
Washington’s House and Senate have both approved the “Washington Psilocybin Services Act” (SB 5263) and the bill awaits Governor Jay Inslee’s signature. Psilocybin is a schedule I drug under the federal Controlled Substances Act and is the psychoactive or “hallucinogenic” component of magic mushrooms. Washington appears set to follow in the footsteps of Oregon and
The Oregon psilocybin program has a residency requirement. I explained how it works here, and wrote “queue the crazy business structures.” Because the program is off to a slow start (see here and here) I haven’t received as many crazy requests as expected. Well, that changed last week when I received a proposal that made
On April 12th, Hilary Bricken moderated our firm’s webinar titled “Current Ketamine Regulations & The Future of Psychedelic Medicines.” In that webinar, Hilary, Griffen Thorne, and I (Ethan Minkin) discussed the new proposed telehealth regulations from the DEA regarding the Ryan Haight Act of 2008 that will undoubtedly affect the ketamine telehealth industry. We also discussed
Last week, the Oregon Health Authority (OHA) awarded a pair of psilocybin manufacturer licenses. First two! Congrats to Tori Arbrust of Satori Farms PDX, and Andres Met of Satya Therapeutics, known to many of us from the Oregon cannabis program. We should also congratulate OHA, which had aimed to issue manufacturing licenses by the end
Click HERE to register for our upcoming FREE Q&A webinar on ketamine regulations and the future of therapeutic psychedelic medicines! In the next few years, the FDA will likely approve drug formulations containing psilocybin and MDMA. While there are still many unknowns concerning how psilocybin and MDMA-based drug therapies will be regulated, we believe that
Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi. Commonly found in tablet or crystal form, MDMA is a potent psychoactive drug with stimulant properties that produces experiences of empathy and sympathy. Both are currently prohibited in Australia, but will soon be available for therapeutic use. In so
Our marketing people somehow determined that I should write a piece comparing Oregon’s new psilocybin program with The Last of Us– which is a zombie show about a global pandemic caused by a mass fungal infection. Apparently this type of content gets a lot of eyeballs. I said: I don’t want to watch a whole
It seems that the Oregon psilocybin program is off to a slow start. The Oregon Health Authority (OHA) did a good job meeting the Measure 109 rulemaking and development deadlines, including by opening the license application portal back on January 2. Still, a slew of factors, some of them structural, have tempered program launch. The
The 2023 Oregon legislative session commenced last week. It’s a regular session this year, so we’re in for a longer stretch– a 160 day calendar, versus the 35 day affair we see in even-numbered years. For better or worse, the legislature has ample time to tinker with our brand-new psilocybin program here in Oregon. Going
